North Carolina State University is seeking a commercial partner to commercialize a new Anti-PD1 Antibody delivery system.
It is important to prevent cancer relapse after resection of tumors, as a rapid cancer progression may occur due to a surgically induced inflammatory response. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. A new class of drugs that block PD-1, the PD-1 inhibitors, activate the immune system to attack tumors and are therefore used with varying success to treat some types of cancer. The delivery of PD-1 Antibodies for cancer treatment has met with varying success.
Researchers at North Carolina State University have developed an inflammation-triggered combination delivery of anti-PD=1 antibody and CpG oligodeoxynucleotides (CpG ODNs) for post-surgery treatment. The delivery carrier, designated as DNA “nanoclew” (DNC), is weaved through the rolling circle amplification using a CpG ODN-encoded template. After injection into the tumor resection sites, TGMS nanoparticles are disassembled upon the digestion of inflammatory-associated proteases to release the caged enzyme, allowing fragmentation of DNCs into CpG ODNs and releasing aPD-1. Using the mouse melanoma-tumor resection model, we demonstrate that a systemic antitumor immune response is generated, significantly inhibiting tumor relapse and metastasis compared to the conventional delivery modalities.
About the Inventor
Dr. Zhen Gu is an Assistant Professor in the joint Department of Biomedical Engineering at North Carolina State University and the University of North Carolina at Chapel Hill. His work also supports the Molecular Pharmaceutics Division at the UNC Eshelman School of Pharmacy and Department of Medicine. His research interests include nanomedicine applications for anti-cancer and anti-diabetes as well as novel drug delivery formulations. Previously, Dr. Gu was a postdoctoral research scientist working with Dr. Robert Langer at the Massachusetts Institutes of Technology.